undamentalytics Newsletter
Sign in

Clene Inc. revenue

Clene Inc.'s revenue was $200,000 in fiscal 2025, down 41.5% on the year before. Since fiscal 2020 ($206,000) it has grown at a compound -0.6% a year. Over the last twelve months it was $197,000.

Revenue history

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue206723473654342200197
Growth on the year before—+251.0%−34.6%+38.3%−47.7%−41.5%—
Gross profit—434447533272157138

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Products $119,000 59.5% ▼ 49.8%
Royalty $81,000 40.5% ▼ 22.9%

From Clene Inc.'s 10-K filed March 17, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Clene Inc. $197,000 -31.1% -36.9%
Celldex Therapeutics, Inc. $158,000 -97.3% -63.5%
Cervomed Inc. $331,295 -95.7% -52.7%
Ibio, Inc. $100,000 -75.0% -62.4%
Lisata Therapeutics, Inc. $100,000 -90.7% —
AIM Immunotech Inc. $95,000 -21.5% -17.3%

Compare with peers

Head to head: CLDX vs CLNNCLNN vs CRVOCLNN vs IBIO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Clene Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Clene Inc.